BackCelldex Therapeutics Overview
Celldex Therapeutics Inc.

Celldex Therapeutics Target Price

Where could CLDX trade next? Consensus target price: $63.

Get informed when a big investor buys or sells

+ Follow

Share Price

$31.1

Average Target Price

$62.57101.2% upside

14 analysts in the last 4 months

High: $100 | Low: $40

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-23Leerink PartnersThomas Smith$88183% upsideOpen
2026-09-23Morgan Stanley$5783.3% upsideOpen
2026-09-22Stifel NicolausAlex Thompson$68118.6% upsideOpen
2026-09-22H.C. WainwrightJoseph Pantginis$64105.8% upsideOpen
2026-09-10Morgan StanleyJudah Frommer$5060.8% upsideOpen
2026-08-07Barclays$5370.4% upsideOpen
2026-07-29Wells Fargo$72131.5% upsideOpen
2026-07-22Cantor Fitzgerald$6196.1% upsideOpen
2026-07-22Wells Fargo$4854.3% upsideOpen
2026-07-22Morgan Stanley$4028.6% upsideOpen
2026-07-22Canaccord Genuity$6092.9% upsideOpen
2026-07-22Leerink Partners$70125.1% upsideOpen
2026-07-20GuggenheimYatin Suneja$100221.5% upsideOpen
2026-06-10UBS$4544.7% upsideOpen
2026-05-13Wells FargoDerek Archila$5473.6% upsideOpen
2026-05-08Barclays$4854.3% upsideOpen
2026-04-20Barclays$4544.7% upsideOpen
2025-12-17Barclays$2422.8% downsideOpen
2025-11-11Barclays$2132.5% downsideOpen
2025-10-13Barclays$2519.6% downsideOpen
2025-03-20Morgan Stanley$4647.9% upsideOpen
2024-10-29H.C. WainwrightJoseph Pantginis$80157.2% upsideOpen
2024-09-25Wells FargoDerek Archila$4441.5% upsideOpen
2024-06-17Stifel NicolausAlex Thompson$5886.5% upsideOpen
2023-11-10Wells FargoDerek Archila$2713.2% downsideOpen
2022-11-11Guggenheim$63102.6% upsideOpen

Celldex Therapeutics (CLDX) FAQ

Celldex Therapeutics's target price stands at $63. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $63 for CLDX implies 101.2% upside versus today's price ($31.1). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Celldex Therapeutics's target price evolved across reporting periods, while the comparison chart places CLDX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Celldex Therapeutics's reading of $63 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.